thyroxine has been researched along with Osteoporosis, Postmenopausal in 32 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 7.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| " Fifty-four postmenopausal women on long-term treatment with thyroxine for primary hypothyroidism, who showed suppressed thyroid stimulating hormone levels were enrolled in our study." | 7.69 | Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. ( Affinito, P; Canciello, P; di Carlo, C; Farace, MJ; Moccia, G; Nappi, C; Palomba, S; Sorrentino, C, 1996) |
| " The presence of primary autoimmune hypothyroidism makes this case specific, since the inability for optimal substitution therapy with a high daily dose of levothyroxine provoked the suspicion of celiac disease." | 3.81 | Osteoporosis reversibility in a patient with celiac disease and primary autoimmune hypothyroidism on gluten free diet--a case report. ( Bajkin, I; Ičin, T; Kovačev-Zavišić, B; Medić-Stojanoska, M; Novaković-Paro, J, 2015) |
| " The aim of this study was to evaluate the effect of antibone resorptive agents, in particular alendronate (ALN) on BMD in postmenopausal osteoporotic women with thyroid carcinoma who were receiving long-term thyrotropin (TSH)-suppressive therapy with thyroxine." | 3.75 | Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. ( Assante, R; Fonderico, F; Lupoli, G; Lupoli, GA; Marciello, F; Martinelli, A; Panico, A, 2009) |
| "To determine whether long-term thyroxine therapy in the premenopausal period is a risk factor for the development of secondary osteoporosis and whether women receiving this therapy have increased bone loss during the premenopausal period." | 3.71 | Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. ( Karner, I; Sijanovic, S, 2001) |
| "Hyperthyroidism is a risk factor for osteoporosis, but the relative contributions of the episode of hyperthyroidism and thyroxine replacement for subsequent hyperthyroidism remain uncertain." | 3.69 | Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? ( Grant, DJ; McMurdo, ME; Mole, PA; Paterson, CR, 1995) |
| "To examine whether suppressive doses of thyroxine have any adverse effects on bone, we evaluated various bone metabolic markers (lectin-precipitated alkaline phosphatase, osteocalcin, carboxyl-terminal region of type I collagen propeptide, tartrate-resistant alkaline phosphatase, and urinary excretion of hydroxyproline and pyridinium crosslinks), incidence of vertebral deformity, total body and regional (lumbar spine and radius) bone mineral densities (BMDs), and rates of bone loss in 24 late postmenopausal (more than 5 years after menopause) women who were treated with levothyroxine (L-T4) after total thyroidectomy for differentiated carcinoma." | 3.69 | Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. ( Ashizawa, K; Fujiyama, K; Ito, M; Kimura, H; Kiriyama, T; Nagataki, S; Nagayama, Y; Tsuruta, M; Villadolid, MC; Yokoyama, N, 1995) |
| " The aim of the present study was to evaluate the effects of treatment with alendronate in patients affected by hyperthyroidism and osteoporosis." | 3.69 | Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. ( Affinito, P; Arlotta, F; Cascone, E; Di Carlo, C; Lupoli, G; Nappi, C; Nuzzo, V; Vitale, G; Vollery, M, 1996) |
| " Fifty-four postmenopausal women on long-term treatment with thyroxine for primary hypothyroidism, who showed suppressed thyroid stimulating hormone levels were enrolled in our study." | 3.69 | Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism. ( Affinito, P; Canciello, P; di Carlo, C; Farace, MJ; Moccia, G; Nappi, C; Palomba, S; Sorrentino, C, 1996) |
| "Seventy-eight post-menopausal women who had been treated with thyroxine for primary autoimmune or idiopathic hypothyroidism for a minimum of 5 years, 44 with TSH persistently suppressed and 34 non-suppressed." | 3.68 | Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. ( Davies, RR; Grant, DJ; McMurdo, ME; Mole, PA; Paterson, CR, 1993) |
| "Of 361 women enrolled in a 2-year calcium supplement trial, 18 received thyroxine for hypothyroidism." | 3.68 | Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. ( Dawson-Hughes, B; Harris, S; Sokoll, LJ; Stall, GM, 1990) |
| " However, careful titration of T4 dosage to maintain biochemical euthyroidism is a better way to avoid the adverse effect of T4 on bone." | 2.68 | Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. ( Kung, AW; Yeung, SS, 1996) |
| "The adverse health effects of thyrotoxicosis have been carefully documented and most practitioners are familiar with the clinical consequences for the patient." | 2.40 | Adverse effects of thyroid hormones. ( Williams, JB, 1997) |
| "To elucidate the role of PTH in postmenopausal bone loss, we studied 33 postmenopausal patients who received total thyroidectomy due to thyroid carcinoma." | 1.29 | Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. ( Fujiyama, K; Ito, M; Kiriyama, T; Nagataki, S; Nakata, K; Yamashita, S; Yokoyama, N, 1995) |
| "To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy." | 1.29 | Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. ( Barrett-Connor, EL; Morton, DJ; Schneider, DL, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (56.25) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 6 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mazziotti, G | 1 |
| Formenti, AM | 1 |
| Frara, S | 1 |
| Olivetti, R | 1 |
| Banfi, G | 1 |
| Memo, M | 1 |
| Maroldi, R | 1 |
| Giubbini, R | 1 |
| Giustina, A | 1 |
| van Rijn, LE | 1 |
| Pop, VJ | 1 |
| Williams, GR | 2 |
| Kovačev-Zavišić, B | 1 |
| Ičin, T | 1 |
| Novaković-Paro, J | 1 |
| Medić-Stojanoska, M | 1 |
| Bajkin, I | 1 |
| Hwangbo, Y | 1 |
| Kim, JH | 1 |
| Kim, SW | 1 |
| Park, YJ | 1 |
| Park, DJ | 1 |
| Kim, SY | 1 |
| Shin, CS | 1 |
| Cho, NH | 1 |
| La Vignera, S | 1 |
| Vicari, E | 1 |
| Tumino, S | 1 |
| Ciotta, L | 1 |
| Condorelli, R | 1 |
| Vicari, LO | 1 |
| Calogero, AE | 1 |
| Panico, A | 1 |
| Lupoli, GA | 1 |
| Fonderico, F | 1 |
| Marciello, F | 1 |
| Martinelli, A | 1 |
| Assante, R | 1 |
| Lupoli, G | 2 |
| Pfeilschifter, J | 1 |
| Murphy, E | 1 |
| Glüer, CC | 1 |
| Reid, DM | 1 |
| Felsenberg, D | 1 |
| Roux, C | 1 |
| Eastell, R | 1 |
| Karga, H | 1 |
| Giagourta, I | 1 |
| Papaioannou, G | 1 |
| Katsichti, P | 1 |
| Pardalakis, A | 1 |
| Kassi, G | 1 |
| Zagoreou, A | 1 |
| Triantaphyllopoulou, M | 1 |
| Zerva, C | 1 |
| Nagata, M | 1 |
| Suzuki, A | 1 |
| Sekiguchi, S | 1 |
| Ono, Y | 1 |
| Nishiwaki-Yasuda, K | 1 |
| Itoi, T | 1 |
| Yamamoto, S | 1 |
| Imamura, S | 1 |
| Katoh, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Hashimoto, S | 1 |
| Itoh, M | 1 |
| Grant, DJ | 2 |
| McMurdo, ME | 2 |
| Mole, PA | 2 |
| Paterson, CR | 2 |
| Fujiyama, K | 2 |
| Kiriyama, T | 2 |
| Ito, M | 2 |
| Nakata, K | 1 |
| Yamashita, S | 1 |
| Yokoyama, N | 2 |
| Nagataki, S | 2 |
| Wartofsky, L | 1 |
| Kimura, H | 1 |
| Ashizawa, K | 1 |
| Tsuruta, M | 1 |
| Nagayama, Y | 1 |
| Villadolid, MC | 1 |
| Schneider, DL | 1 |
| Barrett-Connor, EL | 1 |
| Morton, DJ | 1 |
| Cooper, DS | 1 |
| Davies, RR | 1 |
| Katz, S | 1 |
| Tørring, O | 1 |
| Kung, AW | 1 |
| Yeung, SS | 1 |
| Nuzzo, V | 1 |
| Di Carlo, C | 2 |
| Affinito, P | 2 |
| Vollery, M | 1 |
| Vitale, G | 1 |
| Cascone, E | 1 |
| Arlotta, F | 1 |
| Nappi, C | 2 |
| Sorrentino, C | 1 |
| Farace, MJ | 1 |
| Moccia, G | 1 |
| Canciello, P | 1 |
| Palomba, S | 1 |
| Woeber, KA | 1 |
| Zeni, S | 1 |
| Gomez-Acotto, C | 1 |
| Mautalen, C | 1 |
| Williams, JB | 1 |
| Islam, N | 1 |
| Chanda, S | 1 |
| Ghosh, TK | 1 |
| Mitra, C | 1 |
| Ben-Shlomo, A | 1 |
| Hagag, P | 1 |
| Evans, S | 1 |
| Weiss, M | 1 |
| Duntas, LH | 1 |
| Mantzou, E | 1 |
| Koutras, DA | 1 |
| Gyulai, L | 1 |
| Bauer, M | 1 |
| Garcia-Espana, F | 1 |
| Hierholzer, J | 1 |
| Baumgartner, A | 1 |
| Berghöfer, A | 1 |
| Whybrow, PC | 1 |
| Sijanovic, S | 1 |
| Karner, I | 1 |
| Stall, GM | 1 |
| Harris, S | 1 |
| Sokoll, LJ | 1 |
| Dawson-Hughes, B | 1 |
4 reviews available for thyroxine and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
[Bone metabolism and thyroid disease. Normalized bone metabolism prevents osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risk | 1993 |
Subclinical thyroid dysfunction.
Topics: Atrial Fibrillation; Bone Density; Depressive Disorder; Female; Humans; Hypothyroidism; Lipids; Male | 1997 |
Adverse effects of thyroid hormones.
Topics: Aging; Cardiovascular Diseases; Clinical Trials as Topic; Euthyroid Sick Syndromes; Female; Humans; | 1997 |
Managing subclinical hypothyroidism.
Topics: Aged; Female; Humans; Hypothyroidism; Male; Middle Aged; Osteoporosis, Postmenopausal; Thyrotropin; | 1998 |
3 trials available for thyroxine and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Transient changes in thyroid functions tests after zoledronic acid infusion.
Topics: Bone Density Conservation Agents; C-Reactive Protein; Diphosphonates; Female; Humans; Hydrocortisone | 2011 |
Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
Topics: Biomarkers; Bone and Bones; Bone Density; Calcitonin; Calcium; Carcinoma; Female; Humans; Middle Age | 1996 |
Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.
Topics: Aged; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Female; Humans; Kinetics; Middle A | 2001 |
25 other studies available for thyroxine and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone-Suppressive Therapy for Thyroid Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Chemotherapy, Adjuvant; Cross-Sectional Studies; Drug | 2018 |
Low bone mineral density is related to high physiological levels of free thyroxine in peri-menopausal women.
Topics: Bone Density; Bone Diseases, Metabolic; Cross-Sectional Studies; Female; Humans; Iodide Peroxidase; | 2014 |
Osteoporosis reversibility in a patient with celiac disease and primary autoimmune hypothyroidism on gluten free diet--a case report.
Topics: Calcium; Celiac Disease; Cholecalciferol; Diet, Gluten-Free; Female; Humans; Hyperparathyroidism, Se | 2015 |
High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Cohort Studies; Female; Femur Neck; H | 2016 |
L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Body Mass Index; Bone Density; Data Interpretation, St | 2008 |
Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; | 2009 |
[Osteoporosis--current diagnostics and therapy].
Topics: Absorptiometry, Photon; Accidental Falls; Bone Density; Bone Density Conservation Agents; Calcium; C | 2009 |
Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Female; Fractur | 2010 |
Subclinical hypothyroidism is related to lower heel QUS in postmenopausal women.
Topics: Aged; Bone Density; Calcaneus; Female; Humans; Hypothyroidism; Middle Aged; Osteoporosis, Postmenopa | 2007 |
Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women?
Topics: Aged; Bone Density; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans; Hyperthyroidism | 1995 |
Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism.
Topics: Adult; Aged; Bone Density; Calcifediol; Calcitriol; Calcium; Female; Humans; Hypoparathyroidism; Inc | 1995 |
Levothyroxine therapy and osteoporosis. An end to the controversy?
Topics: Bone Density; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Thyroxine | 1995 |
Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women.
Topics: Aged; Aging; Bone Density; Carcinoma; Cross-Sectional Studies; Dose-Response Relationship, Drug; Fem | 1995 |
Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Cross-Sectional Studies; Drug Combina | 1994 |
Thyroid hormone, osteoporosis, and estrogen.
Topics: Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Risk Factors; Thyroxine | 1994 |
Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis.
Topics: Bone Density; Cross-Sectional Studies; Drug Administration Schedule; Female; Forearm; Humans; Hypoth | 1993 |
Outcome of treating hypothyroidism.
Topics: Drug Monitoring; Female; Humans; Hypothyroidism; Osteoporosis, Postmenopausal; Thyroxine | 1993 |
Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole.
Topics: Adult; Alendronate; Bone Density; Female; Humans; Hyperthyroidism; Methimazole; Middle Aged; Osteoca | 1996 |
Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism.
Topics: Bone Density; Bone Remodeling; Case-Control Studies; Cross-Sectional Studies; Female; Humans; Hypoth | 1996 |
The effect of olpadronate in ovariectomized thyroxine-treated rats.
Topics: Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Creatinin | 1997 |
Cold stress facilitates calcium mobilization from bone in an ovariectomized rat model of osteoporosis.
Topics: Alkaline Phosphatase; Animals; Calcium; Calcium-Transporting ATPases; Cold Temperature; Corticostero | 1998 |
Early postmenopausal bone loss in hyperthyroidism.
Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Amino Acids; Bone Density; Case-Control S | 2001 |
Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation.
Topics: Absorptiometry, Photon; Bipolar Disorder; Bone Density; Depressive Disorder, Major; Female; Humans; | 2001 |
Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Topics: Adult; Biomarkers; Bone Density; Calcium; Combined Modality Therapy; Croatia; Female; Humans; Long-T | 2001 |
Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
Topics: Aged; Bone Density; Female; Femur Neck; Humans; Hypothyroidism; Middle Aged; Osteoporosis, Postmenop | 1990 |